Targeted Approaches to CMV Management: Alleviating the Patient Burden from Prevention to Refractory Disease

Program Overview

Cytomegalovirus (CMV) can be a life-altering reality for patients after solid organ transplant (SOT). Limited antivirals and rising resistance make treatment a challenge. Join Drs. Deepali Kumar and Raymund R. Razonable as they share practical, evidence-based strategies to tackle the most common serious infectious complication after SOT. The faculty will be joined by a patient who will speak directly about how her transplant journey was complicated by CMV and what it means for her to navigate this challenging infection on her path towards healing.

 

Credit Expired

Target Audience

Infectious disease, transplantation, and internal medicine clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ updated guidelines in the antiviral prophylaxis and initial management of cytomegalovirus (CMV) in solid organ transplant (SOT) patients
  • Create treatment strategies for refractory or resistant CMV in SOT recipients that integrate the latest guidelines
  • Manage adverse events related to CMV antivirals

Activity Faculty

62-26-1892-SM-002 ATC Kumar

Deepali Kumar, MD, MSc, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
Program Medical Director, Ajmera Transplant Program
University Health Network
Director, University of Toronto Transplant Institute
Toronto, ON, Canada

Razonable_Raymund_2021

Raymund R. Razonable, MD, FIDSA, FAST 

Professor, Medicine
Associate Chair of Education, Division of Infectious Diseases
Mayo Clinic
Rochester, MN

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources